Scandion Oncology: Amended CORIST phase II part 2 approved - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Scandion Oncology: Amended CORIST phase II part 2 approved - Redeye

{newsItem.title}

Redeye briefly comments on Scandion receiving approval for its amended CORIST phase II part 2 proof-of-concept arm. As previously announced, Scandion is expanding the number of trial sites to assure timely completion in Q2-Q3 2022.

Nyheter om Scandion Oncology

Läses av andra just nu

Om aktien Scandion Oncology

Senaste nytt